Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Pediatric sickle cell disease: past successes and future challenges
source: Pediatric Research
year: 2017
authors: Meier ER, Rampersad A
summary/abstract:Once a fatal disease of childhood, more than 95% of patients born today with sickle cell disease (SCD) in developed countries are expected to survive into adulthood, largely because of improvements in supportive and preventive care (newborn screening, penicillin prophylaxis, transcranial Doppler (TCD) screening). Hydroxyurea (HU) therapy, the only oral medication currently available to prevent SCD complications, has become more widespread over the past 20 y. The NHLBI recommends that HU be offered to all patients with HbSS beginning at 9 mo of age, and the recently published Abnormal TCD with Transfusions Changing to HU (TWiTCH) trial has shown HU as an acceptable alternative to transfusion therapy for patients at high risk of stroke. While hematopoietic stem cell transplant (HSCT) is a curative option for SCD, less than 25% of patients have a suitable donor. Alternative stem cell sources from unrelated donors and haplo-identical donors are currently under investigation as are gene therapy trials. This review will focus on early efforts to elucidate SCD pathophysiology as well as supportive and preventive care improvements. Findings from recent multi-center studies (Silent Infarct Transfusion (SIT) Trial and TWiTCH) will be summarized. Finally, HSCT trials and gene therapy will be reviewed.
organization: Indiana Hemophilia and Thrombosis Center, IndianapolisDOI: 10.1038/pr.2016.204
read more full text
Related Content
-
Why Sickle Cell: Ade Adeyokunnu, MBAThe podcast is presented by sickle cell ...
-
Study challenges view that sickle cell trait increases mortality riskSurprising findings from a study of heal...
-
The Truth About Chronic Illness in CollegeAs I write this post I am sitting in my ...
-
Association of Sickle Cell Trait With Hemoglobin A1c in African AmericansIMPORTANCE: Hemoglobin A1c (HbA1c) refle...
-
Sickle Beta Zero Thalassemia DiseaseSickle Beta Zero Thalassemia (Sickle BA-...
-
IASCNAPA Sickle Cell Disease Conference: Treating the Whole PersonDate: April 14-15, 2021 Place: Online/V...
-
6th Annual Chicago Sickle Cell SummitDate & Time Sep 28, 2023 11:00 AM...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.